Fluprevli (Trivalent Seasonal Inactivated Influenza Split Virion) for IM Injection

Fluprevli Trivalent Seasonal Inactivated Influenza Split Virion Vaccine — for IM Injection Protection

Fluprevli is a trivalent seasonal inactivated influenza split virion vaccine formulated for intramuscular injection. Designed to provide robust seasonal flu protection, this prescription-grade vaccine protects against three prevalent influenza virus strains: influenza A (H1N1), influenza A (H3N2), and influenza B/Victoria.

Key Features & Clinical Profile

This split virion vaccine technology delivers targeted immune response with a well-established safety and efficacy profile. Administered via intramuscular injection, typically in the upper arm, Fluprevli is indicated for individuals aged 6 months and older as part of annual seasonal flu immunization protocols.

Vaccine Composition & Protection

The trivalent formulation safeguards against three dominant seasonal influenza viruses expected during the vaccination season. Split virion technology minimizes adverse reactions while maintaining immunogenic potency. Annual vaccination remains essential, as influenza virus strains evolve seasonally.

Clinical Indication & Recommended Use

Fluprevli is recommended annually for all eligible populations, with particular emphasis on high-risk groups including elderly patients, immunocompromised individuals, and those with chronic medical conditions. Healthcare providers should assess individual patient risk profiles and contraindications before administration.

Dosage & Administration

Administer via intramuscular injection according to prescribing guidelines and patient age recommendations. Consultation with a qualified healthcare provider is essential to determine appropriate candidacy and optimal timing within the vaccination schedule.

Storage & Handling

Maintain proper cold-chain management per manufacturer specifications to ensure vaccine potency and safety compliance.